Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE NEW DATA
OTEZLA HAS DATA ACROSS MULTIPLE DOMAINS OF PsA
SELECT AN ENDPOINT TO SEE THE DATA


PALACE 1-3 PRIMARY ENDPOINTS 1,5
- Otezla significantly improved ACR20 response vs placebo at week 16
- PALACE 1: 38% vs 19%, Otezla 30 mg BID (n=168) vs placebo (n=168) (P<0.05)
- PALACE 2: 32% vs 19%, Otezla 30 mg BID (n=162) vs placebo (n=159) (P<0.05)
- PALACE 3: 41% vs 18%, Otezla 30 mg BID (n=167) vs placebo (n=169) (P<0.0001)
PALACE 4 PRIMARY ENDPOINT 5
- PALACE 4: 31% vs 16%, Otezla 30 mg BID (n=176) vs placebo (n=176) (P=0.001)
ACTIVE PRIMARY ENDPOINT 4
- ACTIVE: 38% vs 20%, Otezla 30 mg BID (n=110) vs placebo (n=109) (P<0.005)